PolycapTM is indicated for Secondary Prevention of CVD as it contains following 5 proven and safe therapies commonly recommended and prescribed for secondary prevention.

  • Atenolol (beta-blocker) 50mg for heart rate reduction & BP control
  • Ramipril (ACE inhibitor) 5mg for vasodilation and BP control
  • Hydrochlorothiazide (diuretic) 12.5mg for reducing preload (by Na+ and H2O excretion) and BP control.
  • Simvastatin (HMG CoA reductase inhibitor) 20mg for total cholesterol and LDL reduction.
  • Low dose aspirin (anti-platelet) 100mg to reduce the platelet aggregation.

Yes, clinical trial has been done with PolycapTM in Secondary prevention of CVD.
TIPS 2 study was conducted in 518 patients with established vascular disease and BP≥130/80. Patients studied in TIPS 2 study had multiple risk factors and stable CVD.

TIPS 2 PolycapTM was found efficacious and safe in following group of patients with established vascular disease.

  • Patients with previous myocardial infarction (>7 days post uncomplicated MI)
  • Patients with ischemic heart disease with significant ECG changes
  • Patients with a positive stress test, or stable angina
  • Patients with cerebrovascular disease
  • Patients with previous ischemic stroke
  • Patients with transient ischemic attacks

TIPS 2 study found that PolycapTM can control BP and Lipids in patients with established Vascular Disease and reduces the risk of CHD and stroke and is well tolerated.

TIPS 3 trial (Results published in the NEJM) evaluated the effects of Polycap in the primary prevention of cardiovascular disease and showed that Polycap with Aspirin reduced CVD by 31%, and Polycap alone reduced CVD by 21%.

- PolycapTM dose is 1-2 capsules once a day for CVD patients for Secondary Prevention.

- PolycapTM dose is 1 capsule once a day for Primary Prevention in patients at risk of CV events and stroke.

- PolycapTM is a Low Dose Combination Drug.

- Drug titration with additional therapies can be done along with PolycapTM.

- PolycapTM offers 5 proven and safe drugs recommended for Secondary Prevention in low dose. If a clinician needs to add additional dose for Residual Risk Management, it can be done based on patients blood pressure and lipid profile.

  • To Treat to Target for BP goals, an additional Angiotensin Receptor Blocker or a calcium channel blocker can be prescribed
  • To achieve Lipid Targets, additional dose of simvastatin or ezetimibe or fenofibric acid can be added.

- Therefore, PolycapTM is not a hindrance for dose titration.

- Dose of PolycapTM is once a day preferably morning time.

- HCTZ in the morning

- Netherlands study showed that time does not matter!

- Take any fixed time.

- 1 OD in Primary Prevention

- 2 OD or 1 OD in Secondary Prevention

Can PolycapTM be used in Type 2 Diabetes patients?

  • Yes, PolycapTM can be used in patients with Type 2 Diabetes. TIPS 1 study included 2053 patients and one-third patients in PolycapTM study group were diabetics. Similar reduction in blood pressure lowering was observed in diabetics.
  • The effect of the PolycapTM on LDL cholesterol was greater in participants with diabetes.
  • These findings suggest that the potential relative and absolute benefits of the PolycapTM on clinical outcomes are likely to be larger in high-risk than in low-risk subgroups.

- Therefore, PolycapTM is not a hindrance for dose titration.

- If the BP is not controlled by PolycapTM then increasing any one anti hypertensive drug or addition of another anti-hypertensive can be done.

  • Control rates in hypertension are low [29-31].
  • In population studies across globe, HT control rates as low as
  • 53.1% for the US,
  • 41.0% for Canada,
  • 33.6% for Germany and
  • 29.2% for the UK
  • which illustrate that the high control rates reported in randomized controlled trials do not always translate into clinical practice.

- We could give additionally higher dose of Simvastatin or any other (non-statin) lipid lowering drug such as fibrate or ezetimibe or Niacin.

- No since PolycapTM contains aspirin it cannot be used in Hemorrhagic stroke patients.

- Yes it can be given in asthmatic patients, because at lower doses Atenolol does not loose its selectivity. At higher doses Atenolol (100mg) does lose its selectivity for β receptors and behaves like a non selective molecule.